Posted in | News

Newbridge Nanotechnology Index Announces Quarterly Rebalance

Newbridge Securities Corporation has announced the quarterly rebalancing and reconstitution of its Newbridge Nanotechnology Index. This quarter saw no additions or deletions among the constituents, leaving the total number of companies included at 24.

Constituents subject to the 10% index weight cap were Headwaters, FEI Co., Amcol, and Symyx Technologies. The NNIX ended the quarterly period at 900.07, up 1.9% from the last rebalance on November 17, 2006.

The Newbridge Nanotechnology Index (NNIX) has been constructed to track the stock market performance of companies that are currently active in nanotechnology. The Index is comprised of companies whose operations, based on our assessment of products, intellectual property, research initiatives and partnerships, include a significant focus on nanotechnology. Companies whose market capitalizations are very large relative to the scope of their nanotechnology operations are not included in order to preserve the "pure play" nature of the Index. Only companies with common stock or ADRs listed on a national market or exchange in the U.S. are eligible. The base date for the Index was June 30, 2004, at which time the base value for the Index was set at 1000. The NNIX is market cap weighted, rebalanced quarterly, and now includes 24 companies.

http://www.newbridgesecurities.com

27th February 2007

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.